75 related articles for article (PubMed ID: 24152721)
1. Platelet activation dynamics evaluated using platelet-derived microparticles in Kawasaki disease.
Yahata T; Suzuki C; Yoshioka A; Hamaoka A; Ikeda K
Circ J; 2014; 78(1):188-93. PubMed ID: 24152721
[TBL] [Abstract][Full Text] [Related]
2. The Usefulness of Platelet-derived Microparticle as Biomarker of Antiplatelet Therapy in Kawasaki Disease.
Kim HJ; Choi EH; Lim YJ; Kil HR
J Korean Med Sci; 2017 Jul; 32(7):1147-1153. PubMed ID: 28581272
[TBL] [Abstract][Full Text] [Related]
3. Monocyte platelet aggregates in children with Kawasaki disease- a preliminary study from a tertiary care centre in North-West India.
Vignesh P; Rawat A; Shandilya JK; Singh Sachdeva MU; Ahluwalia J; Singh S
Pediatr Rheumatol Online J; 2021 Mar; 19(1):25. PubMed ID: 33712020
[TBL] [Abstract][Full Text] [Related]
4. The Platelet Lifeline to Cancer: Challenges and Opportunities.
Haemmerle M; Stone RL; Menter DG; Afshar-Kharghan V; Sood AK
Cancer Cell; 2018 Jun; 33(6):965-983. PubMed ID: 29657130
[TBL] [Abstract][Full Text] [Related]
5. Microparticles in multiple sclerosis and clinically isolated syndrome: effect on endothelial barrier function.
Marcos-Ramiro B; Oliva Nacarino P; Serrano-Pertierra E; Blanco-Gelaz MA; Weksler BB; Romero IA; Couraud PO; Tuñón A; López-Larrea C; Millán J; Cernuda-Morollón E
BMC Neurosci; 2014 Sep; 15():110. PubMed ID: 25242463
[TBL] [Abstract][Full Text] [Related]
6. Association between cell-derived microparticles and adverse events in patients with nonpulsatile left ventricular assist devices.
Nascimbene A; Hernandez R; George JK; Parker A; Bergeron AL; Pradhan S; Vijayan KV; Civitello A; Simpson L; Nawrot M; Lee VV; Mallidi HR; Delgado RM; Dong JF; Frazier OH
J Heart Lung Transplant; 2014 May; 33(5):470-7. PubMed ID: 24656391
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of coagulation activation after rhinovirus infection in patients with asthma and healthy control subjects: an observational study.
Majoor CJ; van de Pol MA; Kamphuisen PW; Meijers JC; Molenkamp R; Wolthers KC; van der Poll T; Nieuwland R; Johnston SL; Sterk PJ; Bel EH; Lutter R; van der Sluijs KF
Respir Res; 2014 Feb; 15(1):14. PubMed ID: 24502801
[TBL] [Abstract][Full Text] [Related]
8. Circulating contact-pathway-activating microparticles together with factors IXa and XIa induce spontaneous clotting in plasma of hematology and cardiologic patients.
Lipets E; Vlasova O; Urnova E; Margolin O; Soloveva A; Ostapushchenko O; Andersen J; Ataullakhanov F; Panteleev M
PLoS One; 2014; 9(1):e87692. PubMed ID: 24498168
[TBL] [Abstract][Full Text] [Related]
9. A standardized exercise intervention differentially affects premenopausal and postmenopausal African-American women.
Kretzschmar J; Babbitt DM; Diaz KM; Feairheller DL; Sturgeon KM; Perkins AM; Veerabhadrappa P; Williamson ST; Ling C; Lee H; Grimm H; Thakkar SR; Crabbe DL; Kashem MA; Brown MD
Menopause; 2014 Jun; 21(6):579-84. PubMed ID: 24193297
[TBL] [Abstract][Full Text] [Related]
10. Hemostatic function of apheresis platelets stored at 4°C and 22°C.
Reddoch KM; Pidcoke HF; Montgomery RK; Fedyk CG; Aden JK; Ramasubramanian AK; Cap AP
Shock; 2014 May; 41 Suppl 1(0 1):54-61. PubMed ID: 24169210
[TBL] [Abstract][Full Text] [Related]
11. Platelet-Derived Microparticles: A New Index of Monitoring Platelet Activation and Inflammation in Kawasaki Disease.
Jin J; Wang J; Lu Y; Fan Z; Huang N; Ma L; Yu H
Indian J Pediatr; 2019 Mar; 86(3):250-255. PubMed ID: 30159809
[TBL] [Abstract][Full Text] [Related]
12. Platelet Activation Dynamics in Kawasaki Disease- Revisited.
Vignesh P; Singh S
Indian J Pediatr; 2019 Mar; 86(3):216-217. PubMed ID: 30741390
[No Abstract] [Full Text] [Related]
13. Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose aspirin in the acute stage of Kawasaki disease: study protocol for a randomized controlled trial.
Kuo HC; Guo MM; Lo MH; Hsieh KS; Huang YH
BMC Pediatr; 2018 Jun; 18(1):200. PubMed ID: 29933749
[TBL] [Abstract][Full Text] [Related]
14. Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial).
Aoyagi R; Hamada H; Sato Y; Suzuki H; Onouchi Y; Ebata R; Nagashima K; Terauchi M; Terai M; Hanaoka H; Hata A;
BMJ Open; 2015 Dec; 5(12):e009562. PubMed ID: 26628527
[TBL] [Abstract][Full Text] [Related]
15. Changes in and significance of platelet function and parameters in Kawasaki disease.
Zheng X; Wu W; Zhang Y; Wu G
Sci Rep; 2019 Nov; 9(1):17641. PubMed ID: 31776411
[TBL] [Abstract][Full Text] [Related]
16. [Clinical effect and safety of clopidogrel combined with aspirin in antithrombotic therapy for children with Kawasaki disease complicated by small/medium-sized coronary artery aneurysms].
Liu YL; Wang XM; Chen TT; Shi K; Lu YH; Guo YH; Li Y
Zhongguo Dang Dai Er Ke Za Zhi; 2019 Aug; 21(8):801-805. PubMed ID: 31416506
[TBL] [Abstract][Full Text] [Related]
17. [Platelet-to-lymphocyte ratio as a biomarker for predicting coronary artery lesions in Chinese children with Kawasaki disease: a Meta analysis].
Li YY; Yuan CC; Cai AY; Zhou BJ; Huang T
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Dec; 25(12):1219-1226. PubMed ID: 38112138
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of PDGFRβ alleviates endothelial cell apoptotic injury caused by DRP-1 overexpression and mitochondria fusion failure after mitophagy.
An X; Ma X; Liu H; Song J; Wei T; Zhang R; Zhan X; Li H; Zhou J
Cell Death Dis; 2023 Nov; 14(11):756. PubMed ID: 37980402
[TBL] [Abstract][Full Text] [Related]
19. Platelets exacerbate cardiovascular inflammation in a murine model of Kawasaki disease vasculitis.
Kocatürk B; Lee Y; Nosaka N; Abe M; Martinon D; Lane ME; Moreira D; Chen S; Fishbein MC; Porritt RA; Franklin BS; Noval Rivas M; Arditi M
JCI Insight; 2023 Jul; 8(14):. PubMed ID: 37279077
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
